Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
AstraZeneca unveils $15bn China investment
(Sharecast News) - AstraZeneca is to invest $15bn in China by the end of the decade, the UK drugs giant confirmed on Thursday, as part of the prime minister's visit to the country. The Cambridge-based blue chip plans to develop its existing manufacturing facilities in Wuxi, Taizhou, Qingdao and Beijing, as well as investing further in research and development. Pascal Soriot, chief executive, called it a "landmark" investment.
He said: "Today's landmark investment of $15bn begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing and global public health."
Keir Starmer added that AstraZeneca's "expansion and leadership in China will help the British manufacturer continue to grow, supporting thousands of UK jobs".
Representatives from around 60 business and cultural groups, including AstraZeneca, are accompanying Starmer on the trip to China, the first by a UK prime minister for eight years.
AstraZeneca has ramped up overseas spending in recent months. As well as the $15bn slated for China, it announced last July a $50bn investment to expand US and manufacturing and research capabilities, alongside plans to list directly on Wall Street. It also struck a deal with the White House to cut prices, amid threats of punitive tariffs.
However, it paused a £200m investment in its research site in Cambridge, and shelved plans to expand a vaccine manufacturing plant in Merseyside last January.
China is AstraZeneca's second-largest market after the US. It currently houses two of AstraZeneca's global R&D centres, which have led 20 clinical trials to date, alongside the four manufacturing plants.
AstraZeneca employs around 17,000 people in the country.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
